Nature Communications Publishes Study Showing CytoDyn’s Monoclonal Antibody (Leronlimab) Prevents SHIV Infection in Non-Human Primates; Results Termed “Potentially Ground-Breaking”

On June 7, 2021, CytoDyn Inc. (OTC.QB: CYDY), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced the publication in Nature Communications of a study showing that the company’s monoclonal antibody drug leronlimab prevented non-human primates from being infected with simian human immunodeficiency virus (SHIV), a monkey-human chimeric form of HIV. The results will inform a future human clinical trial evaluating leronlimab as a potential pre-exposure prophylaxis (PrEP), therapy to prevent human infection from the virus that causes AIDs. The open-access Nature Communications article is titled “Antibody-Based CCR5 Blockade Protects Macaques from Mucosal SHIV Transmission.”

Login Or Register To Read Full Story